Research Into the Treatment of Anemia for Critically Ill Patients Admitted to Intensive Care Units (ICU)
Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
Erythropoietin (EPO) is a hormone produced in the kidney. Its function is to stimulate the
production of red cells in the bone marrow. The purpose of this research study is to
demonstrate that the administration EPO to critically ill subjects in the intensive care unit
(ICU) reduces the number of patients requiring red blood cell (RBC) transfusion as compared
with placebo (a liquid without active medicine).
Phase:
Phase 3
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.